Abstract

With the widespread use of gadoxetic acid-enhanced magnetic resonance imaging, liver nodules appearing as hypovascular in the arterial phase and hypointense in the hepatobiliary phase, defined as hypovascular hypointense nodules, are increasingly detected in patients with cirrhosis and are considered precursor nodules. We sought to evaluate the interval to vascularization development in hepatitis C virus/hepatitis B virus co-infected-associated precursor nodules (BC-HHN group) compared with that in hepatitis C virus mono-infected-associated precursor nodules (C-HHN group) in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging. The interval to vascularization development was estimated by the Kaplan-Meier method and compared using the Cox proportional hazards model. The mean intervals to vascularization development in the BC-HHN and C-HHN groups were 272.9±31.1 and 603.8±47.6 days, respectively (p<0.001). The cumulative vascularization development incidence at 6, 12, and 18 months was 44.9%, 73.5%, and 91.8%, respectively, in the BC-HHN group and 16.9%, 39.0%, and 55.8%, respectively, in the C-HHN group (p<0.001). The multivariate analysis showed that the presence of hepatitis B virus co-infection (hazard ratio: 1.819; 95% confidence interval: 1.222–2.707; p = 0.003) and male sex (hazard ratio: 1.753; 95% confidence interval: 1.029–2.985; p = 0.039) were predictors of vascularization development. More than half of the hypovascular hypointense nodules showed high-signal changes on T2-weighted imaging, and almost half of them showed restricted diffusion on diffusion-weighted images, but these did not predict vascularization development. In a hepatitis C virus- and hepatitis B virus-endemic area, such as Taiwan, precursor nodules in the BC-HHN group tended to have shorter intervals to vascularization development, especially in male patients.

Highlights

  • Most patients with hepatitis C experience chronic hepatitis C virus (HCV) mono-infection

  • Most studies have provided substantial evidence to support that hepatitis B virus (HBV) and HCV co-infections increase the risk of fulminant hepatic failure, the progression of liver disease, and the development of hepatocellular carcinoma (HCC) [4, 9]

  • The study involved a retrospective review of 103 HCV-infected patients from 2009 to 2014 who underwent gadoxetic acid-enhanced magnetic resonance imaging (MRI) because of suspicious nodular lesions detected by an ultrasonography surveillance examination for HCC

Read more

Summary

Introduction

Most patients with hepatitis C experience chronic hepatitis C virus (HCV) mono-infection. The prevalence of chronic HBV and HCV infections in the general population in Taiwan is approximately 0.95–2.6% and 13.7–20%, respectively [1,2,3]. The estimated prevalence of HBV and HCV co-infections is about 0.26–2.4% in Taiwan [4, 5]. In patients with HBV and HCV co-infections, clinical presentations and disease outcomes are usually more severe than in patients with mono-infections [6,7,8]. Most studies have provided substantial evidence to support that HBV and HCV co-infections increase the risk of fulminant hepatic failure, the progression of liver disease, and the development of hepatocellular carcinoma (HCC) [4, 9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call